Luminary Group’s Post

As it prepares for an IPO, CAMP4 Therapeutics has lined up a small $1 million upfront pact with BioMarin, a longstanding California biotech that has trimmed its pipeline, changed leadership and laid off many workers as it looks to right its ship. CAMP4 could go public as $CAMP as early as next week after filing for its Nasdaq listing last month. The company could get up to $370 million from the BioMarin partnership, which will focus on creating two antisense oligonucleotides. The startup also has tie-ups with Fulcrum Therapeutics and Eli Lilly. In its infancy, CAMP4 had deals with Biogen and Alnylam but later scrapped those as it shifted course. #camp4 #rnamedicines #regulatoryrna #asos #oligonucleotides #biomarin #biotechpartnership #biotech #ipo

Vancouver's AbCellera got a boost in the pandemic, proving its antibody-discovery technology worked, making a fortune and accelerating expansion plans. Then the money dried up. What's next? Take a look at this Aleksandra Sagan story, which I also had a hand in. #AbCellera #Canada #Biotech #pharmaceuticals #TheLogic

📈 Upstream Bio and CAMP4 Therapeutics Go Public Amid Biotech IPO Recovery Boston-area biotechs Upstream Bio and CAMP4 Therapeutics are set to debut on Nasdaq, marking a potential recovery in the biotech IPO market. 💰 IPO Pricing and Fundraising ✅ Upstream Bio priced its shares at $17 each, raising $255 million by selling 15 million shares. ✅ CAMP4 priced its shares at $11 each, raising $75 million by offering 6.82 million shares, despite being below its targeted range. 🧬 Upstream Bio's Focus on Severe Asthma ➡️ Upstream Bio will use the funds to continue Phase 2 and later-stage trials of verekitug, a TSLP receptor antagonist for severe asthma and chronic rhinosinusitis with nasal polyps. ➡️ The company hopes to compete with Amgen and AstraZeneca’s Tezspire and Blackstone-backed Uniquity Bio’s solrikitug. 🔬 CAMP4's Regulatory RNA Drug Development ➡️ CAMP4 is working on regulatory RNA, with a Phase 1 trial of its CPS1-targeting medicine for urea cycle disorders. ➡️ The company recently added BioMarin to its partnership lineup, joining Fulcrum Therapeutics and Eli Lilly. 🤔 Question for you...? ➡️ As biotech IPOs begin to recover, what should investors consider when evaluating the long-term potential of these newly listed companies in a competitive market? #IPO #Biotech #Nasdaq #UpstreamBio #CAMP4Therapeutics #DrugDevelopment #AsthmaTreatment #RNAResearch #Biopharma

Thoughts on this? >> Pittsburgh biotech startup raises $2.25 million in seed funding - Pittsburgh Post-Gazette >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #healthcare #pharmaceutical #pharma #biotech

Biotech Startups Make Pre-Election Sprint to the Public Markets The performance of newly public entrants in coming weeks will color other startups’ decisions on whether to take the plunge themselves While many early-stage biotechs went public during the IPO boom—some of them companies with technology platforms for discovering new drugs, but none in clinical trials—the three that debuted Friday all have products in clinical studies. And as the IPO market recovers, clinical-stage companies will have the best shot at home-run offerings because they present less risk and are more likely to be acquired in the near term, investors said. “There’s been a pretty meaningful shift away from the platform or preclinical companies,” said Dr. Jim Healy, managing partner of biotech investor Sofinnova Investments . Some market trends bode well for biotech IPOs: Small and midcap stocks in the sector have performed well this year, and top drug companies have been buying smaller biotechs. Also, a reset of private valuations over the past two years means companies going public now are less likely to do so at inflated prices, making them more attractive to buyers, investors said. If despite these tailwinds biotech IPOs perform poorly in coming months, drugmakers seeking to follow them onto public exchanges could struggle. “It’s not just about going public, it’s also about sustained aftermarket performance,” said Andrew W. Lam, PharmD, managing director and head of biotech private equity for healthcare investor Ally Bridge Group. https://lnkd.in/eTM8WgD6

Thoughts on this? >> Pittsburgh biotech startup raises $2.25 million in seed funding - Pittsburgh Post-Gazette >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #biotech #competitivemarketing

In a remarkable journey of resilience and innovation, Dr. Armon Sharei's experience encapsulates the tumultuous yet inspiring path of biotechnology entrepreneurship. From his days at MIT, Sharei developed a groundbreaking technology for delivering materials into cells without causing damage, leading to the founding of SQZ Biotechnologies. The startup saw early success, winning competitions and securing a partnership with Roche, but faced challenges that ultimately led to its liquidation in 2022. Reflecting on the experience, Sharei took a brief hiatus, only to return with a renewed focus on cell therapy delivery through his new venture, Portal Biotechnologies. Portal aims to revolutionize cell therapy with mechanical tools for material delivery into cells, attracting significant interest from the biotech and academic sectors. Sharei's journey from SQZ to Portal exemplifies the spirit of innovation and the determination to overcome setbacks, underscoring the potential of biotechnology to address complex healthcare challenges. #Biotech #Innovation #Entrepreneurship #CellTherapy

A month into 2024, the tech IPO calendar remains blank. But after two years of quiet, biotech IPOs are suddenly making noise. Last week, bladder cancer drug developer CG Oncology priced its IPO above the expected range and raised $380 million. Its shares then jumped 96% on the first day of trading. That offering was followed by Arrivent Biopharma, which raised $175 million and has traded up in price since its IPO. This sudden swell of biopharma offerings could help pave the way for technology companies waiting in the wings. #ipo #biotech #biopharma #offerings #technology #capitalmarkets

Citing recent Pitchbook Biopharma: Biotech financing darkest before the dawn Therapeutics, which raised a $102 million series A in January, is run by a team with experience developing kinase inhibitors at Incyte. Those biotechs and investors left behind including the early-stage, the new and the unlucky — must streamline, refinance on less favorable terms, merge or shut down. “Financing early-stage innovation has been very challenging,” says David Schilansky, co-founder and CEO of European seed financier and biotech builder Home Biosciences. Biotech IPOs in 2024 remain rare, but sums raised in the first half of the year already surpass 2022 and 2023 Corporate VC is stepping up to support early-stage innovation, pushing overall biopharma VC financing to a projected $28 billion for the full year That total won’t beat frothy 2020 or 2021, but still represents healthy growth from pre-pandemic 2019. Selected VCs are in fact raising new funds: Flagship Pioneering raised one worth $3.6 billion in July, following Foresite Capital’s $900-million biotech-focused fund that closed in June 2024. SEC filings suggest a multi-billion-dollar raise is also underway at Arch Venture Partners. Assuming VC fundraising continues at this rate for the rest of the year, 2024 would see $20 billion in new biotech-focused funds, according to investment bank Stifel. That’s below 2021’s peaky $31 billion, but still a substantial step up from the previous decade. Big pharma companies, meanwhile, still have about $1 trillion to spend, according to a recent Ernst & Young report, making them biotech’s best friend as public markets remain tight. Some drugs giants urgently need to fill large sales gaps as best-selling drugs including Merck’s Keytruda lose patent protection this decade. Others, like Novo Nordisk and Eli Lilly, are being showered with cash from their respective obesity/diabetes franchises, Wegovy/Ozempic (semaglutide) and Zep- bound/Mounjaro (tirzepatide). Biotechs that “align themselves with what big pharmas need have a good chance” of success. Winner-take-all for investors, too #biotech #regenerative #medicine #longevity #mRNA #growth #equity #familyoffice #venturecapital

Are IPOs the Next Big Leap for Biotech Innovations? 💡 | As biotech companies CAMP4 Therapeutics and Upstream Bio carve out their ambitions with planned IPOs worth $67 and $182 million respectively, the industry is abuzz with potential game-changing developments. But this begs the question - will these bold milestones truly accelerate innovation or are they part of a bigger trend in the biotech sector? Ready to make waves in your industry too? With Bridgewise's expertise, you can power up your innovations 🚀. Fast-track development of AI solutions and stay ahead of competition! Looking at expanding your business horizons across Europe or United States? Let’s find those golden opportunities together! Being a global corporate development network with access to 160K+ top decision-makers including venture builders from diverse industries, we connect startup founders with angel investors or VCs. The goal at Bridgewise is simple: help innovative tech founders grow their companies significantly by providing critical insights & resources. Click here for more details on CAMP4 and Upstream Bio's big plans 👉 https://lnkd.in/eH3sazsx #Biotech #CAMP4Therapeutics #UpstreamBio #IPO #InnovationAcceleration #TechFounders #InvestorsConnection #GlobalExpansionOpportunities #VentureGrowth